Ovid Therapeutics Inc (OVID)

Apr 05, 2026

OVID.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Apr 05, 2026

Apr 05, 2026

Ovid Therapeutics Inc (OVID) Stock Forecast, Price Targets and Analysts Predictions - gurufocus.com

Apr 05, 2026

Apr 02, 2026

OVID.O Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 02, 2026

Apr 01, 2026

OVID Should I Buy - Intellectia AI

Apr 01, 2026

Apr 01, 2026

OVID News & Events - intellectia.ai

Apr 01, 2026

Apr 01, 2026

IPO Launch: Does Ovid Therapeutics Inc have declining or rising EPSWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn

Apr 01, 2026

Mar 31, 2026

Gains Report: Can Ovid Therapeutics Inc maintain its current growth rate2026 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

Ovid Therapeutics (OVID) price target increased by 14.29% to 4.87 - MSN

Mar 31, 2026

Mar 31, 2026

Rate Hike: Is Ovid Therapeutics Inc still a buy after recent gains2026 Chart Watch & High Accuracy Trade Alerts - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

OVID Therapeutics Inc (NASDAQ:OVID) Passes Minervini's High-Growth Momentum and Trend Template Filters - ChartMill

Mar 30, 2026

Mar 29, 2026

Aug Reactions: How does Ovid Therapeutics Inc score in quality rankingsCEO Change & Weekly Stock Performance Updates - baoquankhu1.vn

Mar 29, 2026

Mar 29, 2026

Aug Big Picture: Does Ovid Therapeutics Inc have declining or rising EPSBuy Signal & Weekly Momentum Stock Picks - baoquankhu1.vn

Mar 29, 2026

Mar 27, 2026

Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at BTIG Research - MarketBeat

Mar 27, 2026

Mar 27, 2026

Ovid spikes as Wedbush moves to Outperform on lead asset - MSN

Mar 27, 2026

Mar 26, 2026

Lifesci Capital Has Negative Estimate for OVID Q1 Earnings - MarketBeat

Mar 26, 2026

Mar 26, 2026

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Brokerages - marketbeat.com

Mar 26, 2026

Mar 25, 2026

Ovid Therapeutics (NASDAQ: OVID) chair exercises 47,333-share warrant at $1.40 - Stock Titan

Mar 25, 2026

Mar 25, 2026

Investors pour $60M into Ovid Therapeutics to advance seizure drugs - Crain's New York Business

Mar 25, 2026

Mar 24, 2026

Ovid Therapeutics' new epilepsy trial data ignites rally - MSN

Mar 24, 2026

Mar 23, 2026

Ovid Therapeutics secures $60M funding to advance epilepsy drug programs - MSN

Mar 23, 2026

Mar 22, 2026

If You Invested $1,000 in Ovid Therapeutics Inc (OVID) - Stock Titan

Mar 22, 2026

Mar 21, 2026

Here's why Ovid Therapeutics stock popped higher today - MSN

Mar 21, 2026

Mar 21, 2026

Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to Hold - MarketBeat

Mar 21, 2026

Mar 20, 2026

Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN

Mar 20, 2026

Mar 20, 2026

Ovid Therapeutics Stock Surges on Positive Drug Trial Data and Financing Plans - StocksToTrade

Mar 20, 2026

Mar 20, 2026

Ovid Shares Surge with Positive Phase 1 Results and Strategic Moves - timothysykes.com

Mar 20, 2026

Mar 20, 2026

Wedbush Forecasts Strong Price Appreciation for Ovid Therapeutics (NASDAQ:OVID) Stock - MarketBeat

Mar 20, 2026

Mar 20, 2026

Ovid Therapeutics (OVID) Sees Price Target Raised by Wedbush | O - gurufocus.com

Mar 20, 2026

Mar 20, 2026

Bond Watch: How does Ovid Therapeutics Inc score in quality rankingsMarket Performance Report & Daily Technical Forecast Reports - baoquankhu1.vn

Mar 20, 2026

Mar 20, 2026

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding - Seeking Alpha

Mar 20, 2026

Mar 20, 2026

Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com

Mar 20, 2026

Mar 20, 2026

B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia

Mar 20, 2026

Mar 20, 2026

B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com

Mar 20, 2026

Mar 20, 2026

Leerink reiterates Ovid Therapeutics stock rating on safety data By Investing.com - Investing.com India

Mar 20, 2026

Mar 19, 2026

Ovid Therapeutics Hits New 52-Week High of $2.50, Marking Major Milestone - Markets Mojo

Mar 19, 2026

Mar 19, 2026

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally - Sahm

Mar 19, 2026

Mar 19, 2026

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results - Sahm

Mar 19, 2026

Mar 19, 2026

Leerink reiterates Ovid Therapeutics stock rating on safety data - Investing.com

Mar 19, 2026

Mar 19, 2026

Ovid Therapeutics advances OV329 epilepsy drug, secures $60M financing - MSN

Mar 19, 2026

Mar 19, 2026

Ovid’s KCC2 direct activator OV-4071 cleared for clinic - BioWorld MedTech

Mar 19, 2026

Mar 19, 2026

Ovid Therapeutics (OVID) Q4 earnings and revenues surpass estimates - msn.com

Mar 19, 2026

Mar 19, 2026

Ovid Therapeutics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:OVID) 2026-03-19 - Seeking Alpha

Mar 19, 2026

Mar 19, 2026

Ovid Therapeutics Shares Surge After Positive Epilepsy Drug Trial Results - MSN

Mar 19, 2026

Mar 19, 2026

Ovid Therapeutics raises $60 million to expand drug development By Investing.com - Investing.com South Africa

Mar 19, 2026